GRAL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Grail Inc (GRAL) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has a first-mover advantage in the multi-cancer early detection market and analysts have shown some optimism following the recent sell-off, the financial performance, technical indicators, and lack of immediate positive catalysts suggest that waiting for more clarity on its growth trajectory and operational stability would be prudent.
The technical indicators show mixed signals. The MACD is positive and expanding, which is a bullish sign, but the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 46.755, with resistance at 50.56 and support at 42.95. This indicates limited upward momentum in the near term.
Analysts have upgraded the stock to Buy after the recent sell-off, citing a potential attractive entry point.
Grail has a first-mover advantage in the multi-cancer early detection market, which is expected to grow significantly.
Leadership continuity with the announcement of a new CEO could stabilize operations.
The NHS-Galleri study missed its primary endpoint, leading to a 50% sell-off and raising questions about the company's ability to achieve broad reimbursement for its Galleri test.
Financial performance remains weak, with negative EPS and gross margins.
The stock has a bearish trend with limited short-term upside potential based on technical indicators.
In Q4 2025, revenue increased by 13.97% YoY to $43.6M, but the company remains unprofitable with a net loss of $99.18M. EPS dropped by 15.92% YoY to -2.43, and gross margin deteriorated significantly to -25.54%. While revenue growth is positive, the overall financial health is concerning.
Analysts are cautiously optimistic. TD Cowen upgraded the stock to Buy with a price target of $65, citing an attractive entry point after the sell-off. Other firms have lowered price targets but maintained Buy or Outperform ratings, reflecting confidence in the company's long-term potential despite recent setbacks.
